April 11, 2017 04:57 PM EDTUpdated April 12, 01:33 PM
Pharma

Neu­ro­crine bags an FDA OK for tar­dive dysk­i­ne­sia, trump­ing Te­va as it preps first com­mer­cial launch

John Carroll

Editor & Founder

Kevin Gor­man, CEO of Neu­ro­crine Bio­sciences, presents at a Jef­feries in­vestor con­fer­ence in 2013. Bloomberg/via Get­ty Im­ages

The FDA has fol­lowed through …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times